

Global Wellness Strategies Inc. (formerly Redfund Capital Corp.)

Condensed Consolidated Interim Financial Statements

For the nine months ended

June 30, 2021

Unaudited – Prepared by Management

(Expressed in Canadian Dollars)

# NOTICE OF NO AUDITOR REVIEW OF CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

The accompanying unaudited condensed consolidated interim financial statements of Global Wellness Strategies Inc. (formerly Redfund Capital Corp.) ("the Company") for the three and nine months ended June 30, 2021 and June 30, 2020, have been prepared by the management of the Company and approved by the Company's Audit Committee and the Company's Board of Directors.

Under National Instrument 51-102, Part 4, subsection 4.3 (3) (a), if an auditor has not performed a review of the interim financial statements, they must be accompanied by a notice indicating that an auditor has not reviewed the financial statements.

The accompanying unaudited condensed consolidated interim financial statements of the Company have been prepared by and are the responsibility of the Company's management. The Company's independent auditor has not performed a review of these financial statements in accordance with standards established by CPA Canada for a review of the condensed consolidated interim financial statements by an entity's auditor.

# **Condensed Consolidated Interim Statements of Financial Position**

(Unaudited - Prepared by management)

As at June 30, 2021 and So	eptember 30.	2020
----------------------------	--------------	------

		June 30,	September 30,
	<b>N</b> 1 (	2021	2020
Annata	Note	\$	\$
Assets Current assets			
Cash		31,960	3,999
Total assets		31,960	3,999
1000 03500		01,000	0,000
Liabilities and shareholders' deficit			
Current liabilities			
Accounts payable and accrued liabilities	7	403,789	264,654
· ·		403,789	264,654
Non-current liabilities			
Loan payable	9	75,773	-
Total liabilities		479,562	264,654
Shareholders' deficit			
Share capital	5	30,972,073	30,134,573
Reserves	5	6,543,858	6,529,801
Subscriptions received in advance		45,050	-
Deficit		(38,008,583)	(36,925,029)
Total shareholders' deficit		(447,602)	(260,655)
Total liabilities and shareholders' deficit		31,960	3,999
Nature of operations and going concern	1		
Event after the reporting period	11		
_ ront and roporting portion			
Approved on behalf of the Board of Directors on August 30, 2021	:		
"Meris Kott" Director	"Lindsey Perry Jr."	Direct	or

Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Deficit)

(Unaudited - Prepared by management)

# For the nine months ended June 30, 2021 and June 30, 2020

	Number of shares #	Share capital \$	Reserves \$	Subscriptions received in advance \$	Deficit \$	Total shareholders' equity (deficit) \$
October 1, 2019	12,854,237	29,679,528	6,869,055	-	(35,938,796)	609,787
Acquisition of Sunshine State Tea	1,125,000	270,000	-		-	270,000
Shares issued for services	771,323	185,044	-	-	-	185,044
Share-based payments	-	-	47,676	-	-	47,676
Loss and comprehensive loss for the period	-	-	-	-	(186,234)	(186,234)
June 30, 2020	14,750,560	30,134,572	6,916,731	-	(36,125,030)	926,273
October 1, 2020	14,750,560	30,134,573	6,529,801	-	(36,925,029)	(260,655)
Shares issued for services	2,044,124	400,000	-	-	-	400,000
Acquisition of Kaleidomyco LLC	1,750,000	437,500	-	-	-	437,500
Share-based payments	-	-	48,300	-	-	48,300
Subscriptions received in advance	-	-	-	45,050	-	45,050
Re-allocated on expiry of options	-	-	(34,243)	-	34,243	-
Loss and comprehensive loss for the period	-	-	-	-	(1,117,797)	(1,117,797)
June 30, 2021	18,544,684	30,972,073	6,543,858	45,050	(38,008,583)	(447,602)

# Global Wellness Strategies Inc. (formerly Redfund Capital Corp.) Condensed Consolidated Interim Statements of Loss and Comprehensive Loss

(Unaudited – Prepared by management)

# For the three and nine months ended June 30, 2021 and June 30, 2020

		Three montl	ns ended	Nine months	s ended
		June 30, 2021	June 30, 2020	June 30, 2021	June 30, 2020
	Note	\$	\$	\$	\$
Income					
Interest income		-	25,331	-	76,272
Other income			1,385	-	1,385
		-	26,716	-	77,657
Expenses					
Bank charges		384	419	1,140	1,409
Consulting	5,7	37,291	134,500	297,291	186,826
Consumer brands marketing		225,336	-	225,336	-
Office and rent		6,748	121	9,346	4,979
Professional fees	7	11,025	10,500	144,991	38,575
Regulatory and filing		4,977	3,664	51,866	19,826
Share-based payments	3,5,7	437,500	47,676	485,800	47,676
Travel	7	8,000	=	8,000	10,359
Loss from operating expenses		(731,261)	(170,164)	(1,223,770)	(231,993)
Gain on contract settlement	5	121,000	-	106,328	24,000
Unrealized gain on convertible loans receivable, net		-	48,632	-	21,571
Foreign exchange gain (loss)		(342)	257	(355)	188
Loss and comprehensive loss for the period		(610,603)	(121,275)	(1,117,797)	(186,234)
Loss per share					
Weighted average number of common shares outstanding	^	40 =40 = 11	40,000,040	48 000 000	40.045.500
- Basic #	6	16,710,711	13,038,248	15,803,926	12,945,508
- Diluted #	6	16,710,711	13,038,248	15,803,926	12,945,508
Basic loss per share \$	6	(0.04)	(0.01)	(0.07)	(0.01)
Diluted loss per share \$	6	(0.04)	(0.01)	(0.07)	(0.01)

# **Condensed Consolidated Interim Statements of Cash Flows**

(Unaudited - Prepared by management)

For the nine months ended June 30, 2021 and June 30, 2020

		June 30, 2021	June 30, 2020
	Note	\$	\$
Operating activities			
Loss for the period		(1,117,797)	(186,234)
Adjustments for:		, ,	` '
Share-based payments		485,800	47,676
Shares issued for services		400,000	185,044
Unrealized gain on convertible loans receivable, net		-	(21,571)
Accrued interest		748	(42,557)
Net change in non-cash working capital items	8	139,135	(33,211
		(92,114)	(50,853)
Financing activities			
Proceeds from loan payable		75,025	
Subscriptions received in advance		45,050	
		120,075	
Investing activities			
Interest income received on convertible notes		_	33,715
		-	33,715
Net change in cash		27,961	(17,138)
Cash, beginning of period		3,999	18,280
Cash, end of period		31,960	1,142

Supplemental cash flow information

8

# Notes to the Condensed Consolidated Interim Financial Statements

(Unaudited - Prepared by management)

For the nine months ended June 30, 2021 and June 30, 2020

#### 1. Nature of operations and going concern

Global Wellness Strategies Inc. (formerly Redfund Capital Corp.) (the "Company") was incorporated under the Business Corporation Act of Alberta on August 31, 1998 and was continued to British Columbia on January 30, 2006. The Company's shares are publicly traded on the Frankfurt Exchange, OTCQB and Canadian Stock Exchange (the "CSE") under the symbol "LOAN".

On August 2, 2018, the Company completed a change of business and corporate name change to become a merchant bank focused on medical cannabis non-THC, CBD and hemp in both Canada and the United States. The head office, principal address and records office of the Company are located at 100 - 1111 Melville St Vancouver, British Columbia V6E 3V6.

On January 22, 2021, the Company consolidated the Company's issued share capital on a ratio of four (4) old common shares for every one (1) new post-consolidated common share (the "Share Consolidation"). All current and comparative references to the number of common shares, weighted average number of common shares, loss per share, stock options and warrants have been restated to give effect to this Share Consolidation. Additionally, the Company changed their name to Global Wellness Strategies Inc.

These condensed consolidated interim financial statements (the "financial statements") have been prepared on a going concern basis which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. As at June 30, 2021, the Company is not able to finance day-to-day activities through operations and continues to incur losses. The continuing operations of the Company are dependent upon its ability to attain profitable operations and generate funds therefrom. This indicates the existence of a material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern. Management intends to finance operating costs with equity financings and loans from directors and companies controlled by directors. If the Company is unable to continue as a going concern, the net realizable value of its assets may be materially less than the amounts on its condensed consolidated interim statement of financial position.

In March 2020 the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally, potentially leading to an economic downturn. It is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak and its effects on the Company's business or ability to raise funds.

#### 2. Significant accounting policies

# (a) Basis of presentation

These financial statements have been prepared in conformity with International Accounting Standard ("IAS") 34, Interim Financial Reporting, using the same accounting policies as detailed in the Company's annual audited consolidated financial statements for the year ended September 30, 2020, and do not include all the information required for full annual financial statements in accordance with International Financial Reporting Standards ("IFRS"), as issued by the International Accounting Standards Board ("IASB") and interpretations of the International Financial Reporting Interpretations Committee ("IFRIC"). It is suggested that these financial statements be read in conjunction with the annual audited financial statements.

These financial statements have been prepared on an historical cost basis, except for financial instruments measured at fair value. In addition, these financial statements have been prepared using the accrual basis of accounting, except for cash flow information.

All amounts in these financial statements are presented in Canadian dollars, which is the functional currency of the Company. See note 2(b) for functional currency details of the Company's subsidiaries.

# **Notes to the Condensed Consolidated Interim Financial Statements**

(Unaudited - Prepared by management)

For the nine months ended June 30, 2021 and June 30, 2020

# 2. Significant accounting policies (continued)

# (b) Basis of consolidation

These financial statements include the accounts of the Company and its subsidiaries. The results of each subsidiary will continue to be included in the consolidated financial statements of the Company until the date that the Company's control over the subsidiary ceases. Control exists when the Company has the power, directly or indirectly, to govern the financial and operating policies of an entity so as to obtain benefits from its activities.

Inter-company balances and transactions, including unrealized income and expenses arising from inter-company transactions, are eliminated on consolidation.

Entity	Incorporation	Status	Functional Currency	Ownership Percentage
Ultra Invest Canada Inc. ("Ultra Invest")	Canada	Inactive	Canadian	100%
Ona Power Oil & Gas Corp ("Ona")	United States	Inactive	US Dollar	100%

# (c) Future changes in accounting policies

A number of new standards, and amendments to standards and interpretations, are not yet effective for the nine months ended June 30, 2021 and have not been applied in preparing the financial statements. These new standards are either not applicable or are not expected to have a significant impact on the Company's consolidated financial statements.

# Notes to the Condensed Consolidated Interim Financial Statements

(Unaudited - Prepared by management)

For the nine months ended June 30, 2021 and June 30, 2020

# 3. Acquisitions and investments

# Mary's Wellness Ltd. ("MWL")

On March 20, 2019, the Company converted its \$100,000 convertible loan receivable to 5% of the common shares in MWL. The investment in MWL was recorded at cost as the Company does not have significant influence nor control over MWL. On September 30, 2019, due to the inability of the Company to obtain recent financial information of MWL and given the Company did not receive any returns from this investment, the Company had impaired this investment to \$nil, resulting in an impairment loss of \$100,000. The Company assessed the investment at June 30, 2021 and no reversal of impairment was noted.

# Sunshine State Tea Company, LLC ("SSTC")

On February 6, 2020, the Company entered into a Limited Liability Company Membership Interest Purchase Agreement (the "Agreement") with SSTC, a private Florida, United States company controlled by the Company's CEO, Meris Kott, to purchase 18% membership interest in SSTC. The assets in SSTC include formulas related to SSTC tea product line.

On April 1, 2020, the Company issued 1,125,000 common shares to Meris Kott, to acquire an 18% membership interest of SSTC. As additional consideration of the transaction, the Company shall loan the sum of \$500,000 to SSTC for project and business development over the next 3 years, which the loan shall be repaid within 5 years from the date of the last funding and shall bear interest at 6% per annum. This acquisition has been accounted for as a asset acquisition as SSTC does not meet the definition of a business under *IFRS 3, Business Combinations*.

In accordance with *IFRS 2 – Share based payments*, the equity consideration on transfer was measured at fair value on the date of acquisition, which is the date control was obtained.

Consideration paid:	
1,125,000 common shares at \$0.24 per share	\$ 270,000

The fair value share consideration pertaining to the asset acquisition was \$270,000. The consideration paid was recognized as share-based payments in the amount of \$270,000 during the year ended September 30, 2020.

# KaleidoMyco, LLC ("KM")

On April 5, 2021, the Company entered into a Limited Liability Company Membership Interest Purchase Agreement (the "Agreement") with KM, a private Florida, United States company, to acquire up to 100% membership interest in KM. The assets in KM include formulas related to KM's product line.

The Company shall purchase all the membership interest in KM in one (1) tranche representing a 70% membership interest and the second (2) tranche representing a 30% membership interest.

In consideration for the purchase of the assets and membership interests, the Company shall pay KM the following:

- A. \$2,000,000 ("Purchase Price") in common shares of the Company with additional contingent consideration based on performance of the assets.
- B. Bonus of value to \$2,500,000 in common shares of the Company if the assets realize \$2,000,000 in revenues in year two following closing.

The Purchase Price shall be tendered as follows:

- (i) \$1,000,000 in common shares upon closing, payable in three instalments representing a 70% of membership interest as follows:
  - a. \$350,000 in common shares (completed) upon signing of definitive agreement;
  - b. \$400,000 in common shares (\$87,500 issued) on or before August 5, 2021; and
  - c. \$250,000 in common shares on or before December 5, 2021.
- (ii) \$1,000,000 in common shares for the remaining 30% of the membership interest.

# **Notes to the Condensed Consolidated Interim Financial Statements**

# (Unaudited - Prepared by management)

For the nine months ended June 30, 2021 and June 30, 2020

# 3. Acquisitions and investments (continued)

# KaleidoMyco, LLC ("KM") (continued)

This acquisition has been accounted for as a asset acquisition as KM does not meet the definition of a business under *IFRS 3, Business Combinations*.

In accordance with *IFRS 2 – Share based payments*, the equity consideration on transfer was measured at fair value on the date of acquisition, which is the date control was obtained.

Consideration incurred:	
1,750,000 common shares at \$0.25 per share	\$ 437,500

The fair value share consideration pertaining to the asset acquisition is \$437,500. The consideration paid was recognized as share-based payments in the amount of \$437,500 during the nine months ended June 30, 2021.

# 4. Convertible loans receivable

		Convertible loans re	eceivable
		 Face value Fai	r value
Balance, September 30, 2019		\$ 741,809	726,886
Biominerales Pharma Corp.			
	Loan balance	499,135	495,288
	Fair value adjustments	-	9,712
	Interest income received	(47,187)	-
	Interest income accrued	70,894	-
	Impairment of convertible receivable	(522,842)	(505,000)
		-	-
RxMM Health Capital Inc.			
	Loan balance	242,674	231,598
	Fair value adjustments	-	59,997
	Interest income accrued	30,988	-
	Impairment of convertible receivable	(273,662)	(291,595)
		-	-
Balance, September 30, 2020 a	nd June 30, 2021	\$ -	-

# **Notes to the Condensed Consolidated Interim Financial Statements**

(Unaudited - Prepared by management)

For the nine months ended June 30, 2021 and June 30, 2020

# 4. Convertible loans receivable (continued)

#### Biolog, Inc.

On August 21, 2018 ("Effective Date"), the Company subscribed for a convertible secured promissory note with Biolog, Inc. ("Biolog"), a private company incorporated in the State of Utah. The Company has agreed to advance up to USD\$800,000 in tranches. Advances are secured by the assets of Biolog and bear interest at 14%, payable monthly, and the promissory note is due on September 1, 2020. On the Effective Date, the Company advanced \$194,000. The note may be converted into common shares of Biolog at a price equal to a 10% discount to the valuation of Biolog immediately from any financing immediately prior to the date of conversion.

In addition, Biolog issued warrants equivalent to 20% of the amount of the note based upon its valuation as of the Effective Date which is stipulated to be USD\$10,000,000. The option to settle the convertible note and warrants in common shares of Biolog represents an embedded derivative in the form of a call option to the Company. Biolog is a private company and its shares cannot be reliably valued using any market-derived indicators. Accordingly, the derivative asset was initially recognized by the Company at \$nil value. As at September 30, 2019 and September 30, 2020, the fair value of the derivative asset remained the same.

Management completed a thorough analysis as to any expected credit losses on certain of its financial assets. Accordingly, management has been unable to review financial information of Biolog and has assessed the high likelihood of un-collectability in respect to the principal portion of the loan. Thus, the entire balance of convertible note receivable remains impaired. As such time the loan is repaid in full, the Company will recognize a recovery of the impairment amount. This loan continues to be secured by the borrowers' assets. As at September 30, 2020 and June 30, 2021, the loan was in default. The Company will be taking the steps of recovery through the borrowers' assets.

#### Biominerales Pharma Corp.

On August 27, 2018 ("Effective Date"), the Company subscribed for a convertible secured promissory note with Biominerales Pharma Corp. ("Biopharma"), a private company incorporated under the laws of the Province of Quebec. The Company has agreed to advance up to USD\$196,184. Advances are secured by the assets of Biopharma and bears interest at 14% annually, payable monthly; and the promissory note is due on October 1, 2020. On the Effective Date, the Company advanced \$255,000 under the note. The note may be converted into common shares of Biopharma at a price equal to a 10% discount to the price assigned to the common shares of Biopharma from any financing immediately prior to the date of conversion. The Company is not able to exert significant influence over the operations of Biopharma.

In addition, Biopharma issued 18,684 warrants, exercisable at a price of \$2.10 per warrant, to acquire one Class A common share in the capital of Biopharma for a period of 24 months. The option to settle the convertible note and the stock warrants in Class A common shares of Biopharma represents an embedded derivative in the form of a call option. Biopharma is a private company and its shares cannot be reliably valued using any market-derived indicators. As at September 30, 2018, the Company had not received repayment of such note and management has assessed the high likelihood of collectability. Thus, the entire balance of convertible note receivable had been impaired.

On October 1, 2018, a further \$250,000 was loaned to Biopharma under the same terms as the previously loaned \$255,000. This loan continues to be secured by the borrowers' assets. During the period ended September 30, 2020, Biopharma has made monthly interest payments in accordance with the promissory note totaling \$47,176.

Management completed a thorough analysis as to any expected credit losses on certain of its financial assets. Accordingly, management has not been satisfied through the review of financial information of Biominerales and has assessed the high likelihood of un-collectability in respect to the principal portion of the loan. Thus, the entire balance of convertible note receivable was impaired \$505,000 as at September 30, 2020.

During the nine months ended June 30, 2021, the Company extended the loan payable maturity date to October 31, 2021. Biopharma has not made monthly interest payments in accordance with the promissory note.

# **Notes to the Condensed Consolidated Interim Financial Statements**

(Unaudited - Prepared by management)

For the nine months ended June 30, 2021 and June 30, 2020

#### 4. Convertible loans receivable (continued)

#### **RxMM Health Capital Inc.**

On October 1, 2018, the Company entered into a US\$500,000 promissory note with RxMM Health ("RxMM"). The loan is secured by a general security agreement on assets of RxMM. The loan bears an interest at 14% compounded monthly and is repayable within 24 months. Furthermore, RxMM granted additional consideration to the Company providing an option to purchase common shares of RxMM equal to 20% of the amount of the loan based on a valuation agreed upon between RxMM and the Company. On October 9, 2018, the Company made a first tranche loan of \$220,740 CDN to RxMM. This loan continues to be secured by the borrowers' assets.

Management completed a thorough analysis as to any expected credit losses on certain of its financial assets. Accordingly, management has been unable to review financial information of RxMM and has assessed the high likelihood of un-collectability in respect to the principal portion of the loan. Thus, the entire balance of convertible note receivable has been impaired. As such time the loan is repaid in full, the Company will recognize a recovery of the impairment amount. This loan continues to be secured by the borrowers' assets. As at September 30, 2020 and June 30, 2021, the loan was in default. The Company will be taking the steps of recovery through the borrowers' assets.

# Mary's Wellness Ltd.

On October 15, 2018, the Company entered into a \$1,000,000 promissory note with Mary's Wellness Ltd. ("MWL"). The loan was secured by a general security agreement on assets of MWL. The loan bore an interest rate of 12.5% per annum compounded monthly and was repayable by November 1, 2020. Furthermore, MWL granted additional consideration to the Company providing an option to purchase common shares of MWL equal to 20% of the amount of the loan based on a valuation agreed upon between MWL and the Company. On October 19, 2018, the Company made a first tranche loan of \$100,000 CDN to MWL. This loan was secured by the borrowers' assets. The entire loan was converted on March 20, 2019 to a 5% equity interest in MWL (Note 3).

# Winterlife Inc.

On November 1, 2018, the Company entered into a USD\$1,000,000 promissory note with Winterlife Inc. ("Winterlife"). The loan is secured by a general security agreement on assets of Winterlife made effective on November 1, 2018. The loan bears an interest rate of 14% per annum compounded monthly and is repayable by November 1, 2020. Furthermore, Winterlife granted additional consideration to the Company providing an option to purchase common shares of Winterlife equal to 20% of the amount of the loan based on a valuation agreed upon between Winterlife and the Company. On November 6, 2018, the Company made a first tranche loan of \$100,080 CDN to Winterlife. This loan continues to be secured by the borrowers' assets.

Management completed a thorough analysis as to any expected credit losses on certain of its financial assets. Accordingly, management has been unable to review financial information of Winterlife and has assessed the high likelihood of un-collectability in respect to the principal portion of the loan. Thus, the entire balance of convertible note receivable has been impaired. As such time the loan is repaid in full, the Company will recognize a recovery of the impairment amount. This loan continues to be secured by the borrowers' assets. As at September 30, 2020 and June 30, 2021, the loan was in default. The Company will be taking the steps of recovery through the borrowers' assets.

# **Notes to the Condensed Consolidated Interim Financial Statements**

(Unaudited - Prepared by management)

For the nine months ended June 30, 2021 and June 30, 2020

#### 5. Share capital

The authorized share capital of the Company consists of unlimited common shares without par value and unlimited preferred shares without par value. All issued shares are fully paid. No preferred shares have been issued from incorporation to June 30, 2021.

# Transactions for the issue of share capital during the nine months ended June 30, 2021:

The Company issued a total of 2,044,124 common shares to consultants and an officer on the following dates for consulting and professional services rendered:

- November 10, 2020: 500,000 shares for \$60,000 (\$0.12 per share);
- November 11, 2020: 500,000 shares for \$60,000 (\$0.12 per share);
- January 14, 2021: 104,124 shares for \$25,000 (\$0.24 per share);
- February 24, 2021: 740,000 shares for \$201,000 (\$0.27 per share); and
- April 14, 2021: 200,000 shares for \$54,000 (\$0.27 per share).

The fair value of shares issued were recognized and included in consulting expenses. In connection with the shares issued for services, the Company recognized a gain on contract settlement in an amount of \$106,328.

On February 2, 2021, the Company announced a raise up to \$1,000,000 through a non-brokered private placement. The offering will consist of up to 4,000,000 common shares of the Company at an issue price of \$0.25. As at June 30, 2021 the Company has received \$45,050 in advance subscriptions, the Company has not closed this financing.

On April 15, 2021, the company issued 350,000 shares at a deemed price of \$0.25 per common share for consideration of membership interest in KM at a deemed value of \$87,500 (Note 3). Each common share is subject to a four month hold restriction.

On April 15, 2021, the company issued 1,400,000 shares at a deemed price of \$0.25 per common share for consideration of membership interest in KM at a deemed value of \$350,000 (Note 3). Each common share is subject to a four month hold restriction.

# Transactions for the issue of share capital during the nine months ended June 30, 2020:

On April 1, 2020, the Company issued 1,125,000 shares at a deemed price of \$0.06 per common share for consideration of an 18% membership interest in SSTC at a deemed value of \$270,000 (Note 3). Each common share is subject to a four month hold restriction.

The Company issued a total of 771,323 shares to consultants on the following dates for consulting services rendered:

- October 2, 2019: 125,000 shares for \$25,001;
- November 4, 2019: 50,000 shares for \$16,000; and
- January 20, 2020: 46,323 shares for \$12,044.
- April 1, 2020: 50,000 shares for \$12,000; and
- May 15, 2020: 500,000 shares for \$120,000.

The fair value of shares issued were included in consulting expenses. In connection with the shares issued for services, the Company recognized a gain on contract settlement in an amount of \$24,000.

# **Notes to the Condensed Consolidated Interim Financial Statements**

#### (Unaudited – Prepared by management)

For the nine months ended June 30, 2021 and June 30, 2020

# 5. Share capital (continued)

# Stock options

The Company has adopted a stock option plan (the "Plan") whereby the Company may from time to grant to Directors, Officers, employees and consultants options to purchase common shares of the Company provided that the number of options granted, including all options granted by the Company to date, does not exceed 10% of the Company's common shares issued and outstanding at the time of granting stock options. Options may be exercised no later than 90 days following cessation of the optionee's position with the Company or 30 days following cessation of an optionee conducting investor relations activities' position.

A summary of the status of the Company's stock options as at June 30, 2021 and September 30, 2020, and changes during the period/year then ended is as follows:

	Nine months ended June 30, 2021		Year ended September 30, 2020	
	Weighted average Options exercise price		Options	Weighted average exercise price
	#	\$	#	\$
Options outstanding, beginning of period/year	487,500	0.47	337,500	1.74
Granted	250,000	0.255	422,500	0.34
Expired/cancelled	(21,250)	2.04	(272,500)	1.84
Options outstanding, end of period/year	716,250	0.35	487,500	0.47

As at June 30, 2021 the Company has stock options outstanding and exercisable as follows:

Options outstanding #	Options exercisable #	Exercise price \$	Expiry date
75,000	75,000	0.68	September 6, 2024
25,000	25,000	0.68	November 19, 2024
328,750	328,750	0.32	May 14, 2025
37,500	37,500	0.32	May 20, 2025
250,000	250,000	0.255	February 24, 2026
716,250	716,250		

The following table summarizes information about the stock options outstanding as at June 30, 2021:

Num	ber of Weig	hted Weighted	d
opt	tions ave	rage average	Э
outsta	anding remain	ning life exercise pr	rice
	# (yea	ars) \$	
716	,250	4.06	0.35

# **Notes to the Condensed Consolidated Interim Financial Statements**

(Unaudited - Prepared by management)

For the nine months ended June 30, 2021 and June 30, 2020

#### 5. Share capital (continued)

#### Stock options (continued)

On November 19, 2019, the Company granted 25,000 options to a Director of the Company. Each option is exercisable into one common share of the Company for \$0.68 per share and expires November 19, 2024. These options had a fair value on grant of \$5,500 using the Black-Scholes option pricing model with the following assumptions: i) exercise price: \$0.68; ii) share price: \$0.34; iii) term: 5 years; iv) volatility: 100%; v) risk-free rate: 1.45%.

On May 14, 2020, the Company granted 360,000 options to Officers, Directors, and consultants of the Company. Each option is exercisable into one common share of the Company for \$0.32 per share and expires May 14, 2025. These options had a fair value on grant of \$42,600 using the Black-Scholes option pricing model with the following assumptions: i) exercise price: \$0.32; ii) share price: \$0.18; iii) term: 5 years; iv) volatility: 100%; v) risk-free rate: 0.36%.

On May 20, 2020, the Company granted 37,500 options to Officers, Directors, and consultants of the Company. Each option is exercisable into one common share of the Company for \$0.32 per share and expires May 20, 2025. These options had a fair value on grant of \$5,100 using the Black-Scholes option pricing model with the following assumptions: i) exercise price: \$0.32; ii) share price: \$0.20; iii) term: 5 years; iv) volatility: 100%; v) risk-free rate: 0.41%.

On February 24, 2021, the Company granted 250,000 options to Officers, Directors, and consultants of the Company. Each option is exercisable into one common share of the Company for \$0.255 per share and expires February 24, 2026. These options had a fair value on grant of \$48,300 using the Black-Scholes option pricing model with the following assumptions: i) exercise price: \$0.255; ii) share price: \$0.26; iii) term: 5 years; iv) volatility: 100%; v) risk-free rate: 0.73%.

Additionally, during the period ended June 30, 2021, 21,250 stock options, exercisable at \$2.04 each have expired. The original fair value of the expired options was \$34,243 and was charged to share-based payments expense and credited to reserves. As a result of the options expired, \$34,243 was reversed from reserves and credited to deficit.

# Warrants

As an incentive to complete private placements, the Company may issue units which include common shares and common share purchase warrants. Using the residual value method, the Company determines whether a value should be allocated to the warrants attached to the units sold in completed private placements.

Finders' warrants may be issued as a private placement share issue cost and are valued using the Black-Scholes option pricing model.

A summary of the status of the Company's warrants as at June 30, 2021 and September 30, 2020, and changes during the period/year then ended is as follows:

	June 30, 2021		September 30, 2020	
	Warrants #	Weighted average exercise price	Warrants #	Weighted average exercise price
Warrants outstanding, beginning of period/year	3,214,395	1.29	5,992,575	1.32
Private placement warrants expired	(2,325,506)	1.57	(2,778,180)	1.36
Warrants outstanding, end of period/year	888,889	0.56	3,214,395	1.29

Nine months anded

Year ended

# **Notes to the Condensed Consolidated Interim Financial Statements**

#### (Unaudited – Prepared by management)

For the nine months ended June 30, 2021 and June 30, 2020

#### Share capital (continued)

#### Warrants (continued)

As at June 30, 2021 the Company had private placement warrants outstanding and exercisable as follows:

 arrants/ tstanding #	Exercise price \$	Expiry date
 888,889	0.56	August 16, 2021
888,889		

Subsequent to the period ended June 30, 2021, all warrants have expired unexercised.

The following table summarizes information about the warrants outstanding as at June 30, 2021:

	Number of	Weighted	Weighted
Exercise	warrants	average	average
Price	outstanding	remaining life	exercise price
\$	#	(years)	\$
0.56	888,889	0.13	0.56
	888,889	0.13	0.56

#### 6. Loss per share

The calculation of basic and diluted loss per share for the period ended June 30, 2021 was based on the loss attributable to common shareholders of \$1,117,797 (2020 - \$186,234) and a weighted average number of common shares outstanding of 15,803,926 (2020 – 12,945,508).

All options and warrants were excluded from the diluted weighted average number of common shares calculation, as their effect would have been anti-dilutive.

# 7. Related party payables and transactions

A number of key management personnel and directors hold positions in other entities that result in them having control or significant influence over the financial or operating policies of these entities. There were no loans to management personnel or Directors, or entities over which they have control or significant influence, during the nine months ended June 30, 2021 or June 30, 2020.

Meris Kott, the Company's President and CEO receives a monthly consulting fee and incentive stock options. All other key management personnel and directors receive no salaries, non-cash benefits (other than incentive stock options), or other remuneration directly from the Company, other than noted below, and there are no employment contracts with them that cannot be terminated without penalty on thirty days notice. Key management personnel and directors participate in the Company's stock option plan.

250,000 stock options (2020 – nil) were granted during the period ended June 30, 2021 to Directors and Officers which had a fair value on grant date of \$48,300 (2020 - \$25,477).

# **Notes to the Condensed Consolidated Interim Financial Statements**

# (Unaudited - Prepared by management)

For the nine months ended June 30, 2021 and June 30, 2020

# 7. Related party payables and transactions (continued)

The Company transacted with the following related parties:

- (a) 1060606 BC Ltd. ("106 BC Ltd.") is a consulting firm over which the CEO of the Company has significant influence and ownership. Charges are for consulting, travel, office rent and administration.
- (c) Stephen Brohman is the Company's CFO. He is a principal of Donaldson Brohman Martin CPA Inc. ("DBM CPA"), a firm in which he has significant influence. DBM CPA provides the Company with professional services.

The aggregate value of transactions and outstanding balances with key management personnel and Directors and entities over which they have control or significant influence were as follows:

	Transactions 9 months ended June 30, 2021 \$	Transactions 9 months ended June 30, 2020 \$	Balances outstanding June 30, 2021 \$	Balances outstanding September 30, 2020 \$
106 BC Ltd.				
<ul> <li>consulting services</li> </ul>	-	43,254	89,991	89,991
- travel	-	10,359	-	-
	-	53,613	89,991	89,991
DBM CPA	56,500	21,000	65,500	32,425
Meris Kott	98,000	-	98,150	17,150
•	154,500	74,613	253,641	139,566

All related party balances are unsecured and are due within thirty days without interest.

The transactions with the key management personnel and Directors are included in operating expenses as follows:

#### (a) Consulting and travel expenses

- Includes Meris Kott fee related to consulting, administrative and travel related expenses.

#### (b) Professional fees

 Includes the accounting services of the Company's current CFO, Stephen Brohman, charged to the Company by DBM CPA.

# **Notes to the Condensed Consolidated Interim Financial Statements**

(Unaudited - Prepared by management)

For the nine months ended June 30, 2021 and June 30, 2020

#### 8. Supplemental cash flow information

Changes in non-cash operating working capital during the nine months ended June 30, 2021 and June 30, 2020 were comprised of the following:

	June 30,	June 30,
	2021	2020
	\$	\$
Receivables and prepayments	-	(97,232)
Accounts payable and accrued liabilities	139,135	55,179
Net change	139,135	(42,053)

During the nine months ended June 30, 2021 and June 30, 2021 there were no non-cash financing or operating activities, additionally, no amounts paid on account of interest or income taxes.

During the nine months ended June 30, 2021 there was non-cash investing activities. The company issued 1,750,000 shares at a deemed price of \$0.25 per common share for membership interest in KM at a deemed value of \$437,500 (Note 3).

During the nine months ended June 30, 2020, there were non-cash investing activities. The company issued 1,125,000 shares at a deemed price of \$0.24 per common share for consideration of an 18% membership interest in SSTC at a deemed value of \$270,000 (Note 3).

During the nine months ended June 30, 2020 there were no amounts paid on account of interest or income taxes.

# 9. Loan Payable

On March 25, 2021 ("Effective Date"), the Company signed an unsecured Balloon Promissory Note (the "Loan") with an arm's length party, whereby the Company received and amount of \$75,025. The Loan bears interest at 4% annually and is due on March 24, 2024 (the "Maturity Date"). Following the Maturity Date both principal and accrued interest shall bear interest at the rate of 8% annually. The Loan may be repaid at any time in whole or in part without penalty.

#### 10. Financial risk management

# Capital management

The Company is a merchant bank and considers items included in shareholders' equity (deficit) as capital. The Company manages its capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of underlying assets. In order to maintain or adjust its capital structure, the Company may issue new shares, purchase shares for cancellation pursuant to normal course issuer bids or make special distributions to shareholders. The Company is not subject to any externally imposed capital requirements and does not presently utilize any quantitative measures to monitor its capital. The Company's capital structure as at June 30, 2021 is comprised of shareholders' deficit of \$447,602 (September 30, 2020 - \$260,655). There were no changes to the Company's management of capital during the nine months ended June 30, 2021.

The Company currently has no source of revenues except for interest received from convertible loans. In order to fund future projects and pay for administrative costs, the Company will spend its existing working capital and raise additional funds as needed. The Company's ability to continue as a going concern on a long-term basis and realize its assets and discharge its liabilities in the normal course of business rather than through a process of forced liquidation is primarily dependent upon its ability to borrow or raise additional financing from equity markets.

# **Notes to the Condensed Consolidated Interim Financial Statements**

# (Unaudited - Prepared by management)

For the nine months ended June 30, 2021 and June 30, 2020

#### 10. Financial risk management (continued)

#### Financial instruments - fair value

The Company's financial instruments consist of cash, accounts payable and accrued liabilities and loan payable.

The carrying value of accounts payable and accrued liabilities and loan payable approximates their fair value because of the short-term nature of these instruments.

Financial instruments measured at fair value on the condensed consolidation interim statements of financial position are summarized into the following fair value hierarchy levels:

Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2: inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

	Level 1 \$	Level 2 \$	Level 3 \$	Total \$
June 30, 2021				
Cash	31,960	-	-	31,960
	31,960	-	-	31,960
September 30, 2020				
Cash	3,999	-	-	3,999
	3,999	-	-	3,999

#### Financial instruments - risk

The Company's financial instruments are exposed to certain financial risks, including credit risk, foreign exchange risk, and liquidity risk.

# a) Credit risk

Credit risk is the risk that one party to a financial instrument will fail to discharge an obligation and cause the other party to incur a financial loss. The Company's primary exposure to credit risk is on its bank account. All of its cash is deposited in a bank account held with a major bank in Canada. As most of the Company's cash is held by one bank there is a concentration of credit risk. This risk is managed by using a major bank that is a high credit quality financial institution as determined by rating agencies. The maximum exposure to credit risk is the carrying amount of the Company's financial instruments.

# b) Foreign exchange risk

Foreign currency risk is the risk that the fair values of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the respective functional currency. The Company is not exposed to significant foreign exchange risk.

# c) Liquidity risk

Liquidity risk arises through the excess of financial obligations over available financial assets due at any point in time. The Company's objective in managing liquidity risk is to maintain sufficient readily available reserves in order to meet its liquidity requirements at any point in time.

Historically, the Company's main source of funding has been the issuance of equity securities for cash, primarily through private placements. The Company's access to financing is always uncertain. There can be no assurance of continued access to significant equity funding.

# **Notes to the Condensed Consolidated Interim Financial Statements**

(Unaudited - Prepared by management)

For the nine months ended June 30, 2021 and June 30, 2020

# 11. Event after the reporting period

On August 6, 2021, the Company signed a definitive agreement to purchase certain assets of Cannvalate Pty. Ltd. ("CV") based in Australia and to acquire 100% of its wholly owned subsidiary, Shanti Therapeutics Pty. Ltd. ("Shanti")

The assets acquired by the Company and sold and owned by CV and managed by Shanti include, but are not limited to, application patents, intellectual property, formulae, compounds, solutions, research, data, techniques, processes, brand names, trade names and trademarks.

The purchase price of \$2,500,000 will be consummated in restricted shares of the Company's common shares in four instalments tendered over an eight-month period, representing 100% of the assets of Shanti. The Company's valuation for tranche issuances will be subject to a 30-day volume-weighted average price (VWAP) with a base share price set at \$0.20. There is an additional contingent consideration of \$2,500,000 to Shanti based on the performance of its assets and specific milestones must be met. Shanti shall have the right to appoint one director to the board of the Company.